Scout Bio
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1831 Delancey Pl, Philadelphia, Pennsylv...Phone Number
(650) 325-5153Website
www.scoutbio.coRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Scout Bio
Scout Bio is a biotechnology company focused on revolutionizing pet medicine through the development of one-time gene therapies and monoclonal antibodies for major chronic health conditions in pets. The company leverages advanced AAV vector technology to induce long-term expression of therapeutic proteins, addressing significant unmet medical needs in companion animals. With a strong partnership with the University of Pennsylvania's Gene Therapy Program, Scout Bio aims to enhance the standard of care for pets suffering from chronic diseases. Their target clients include pet owners and veterinary professionals seeking innovative and effective treatment options for chronic conditions in animals.Explore more
Scout Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Scout Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Scout Bio recently announced quarterly report
Check if Scout Bio has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Scout Bio
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Scout Bio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Scout Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Scout Bio launches new products
Click to see if Scout Bio had a recent Job posting/layoffs
Check out if Scout Bio is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Scout Bio as Masked Content
Find 3 more new buyers
Compare Similar Companies to Scout Bio
Compare insights from companies similar to Scout Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Scout Bio
<$5M
1-10
Private
$62.3M
2016
MW
Matthew WilsonVice President, Product Discovery & External Innovation
$7.7M
11-50
Public
$340.5M
2015
KB
Kristi BalacyHead Senior Director, Clinical Development Operations & of Clinical Operations
Company Profile Activity
Activity Insights
Scout Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Scout Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Scout Bio.
Scout Bio financials insights
Gather financial insights about Scout Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$9.3M
2021
Series B
$53M
Scout Bio Tech Stack
A closer look at the technologies used by Scout Bio
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Funding
Scout Bio News & Media
Scout Bio Announces Appointment of Chief Manufacturing Officer
Experienced global animal health biologics executive to drive manufacturing strategies and advance pipeline of multiple animal health monoclonal antibodies (mAbs) and novel adeno-associated virus (AAV) therapeutics. Experienced global animal health biologics executive to drive manufacturing strategies and advance pipeline of multiple animal health monoclonal antibodies (mAbs) and novel adeno-associated virus (AAV) therapeutics.Scout Bio To Present Positive Clinical Data On SB-001 For Feline CKD-Anemia at Leading Veterinary Medicine Forum
Scout Bio’s research was selected for presentation at the American College of Veterinary Internal Medicine (ACVIM) ForumThree lectures will present Scout Bio’s technology, new areas of research, and positive clinical results from first successful pilot clinical study with SB-001 for feline anemiaFirst time a large multi-center study applying gene therapy to treat a chronic disease will be presented at a veterinary conference PHILADELPHIA, June 14, 2022 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnolScout Bio to Feature at Morgan Stanley Animal Health Biopharma Global KOL Summit
Leading veterinary biopharma innovators, experts, and investors in gene therapy technologies, including Aaron Schacht and Mark Heffernan, to present opportunities for therapeutic innovation in rapidly growing market Leading veterinary biopharma innovators, experts, and investors in gene therapy technologies, including Aaron Schacht and Mark Heffernan, to present opportunities for therapeutic innovation in rapidly growing marketScout Bio Appoints Life Sciences Executive Aaron Schacht to Board of Directors
PHILADELPHIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions announced it had appointed Aaron Schacht to its Board of Directors. Mr. Schacht is a deeply experienced life sciences executive with management expertise across a wide range of functions and will work with Scout Bio to execute its strategic development as a veterinary biopharma pioneer.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Scout Bio
Sign Up For FreeTo access detailed company insights
Scout Bio is a biotechnology company focused on revolutionizing pet medicine through the development of one-time gene therapies and monoclonal antibodies for major chronic health conditions in pets. The company leverages advanced AAV vector technology to induce long-term expression of therapeutic proteins, addressing significant unmet medical needs... Read More
